Corbus Pharmaceuticals Q3 EPS $(1.81) Misses $(1.20) Estimate
Corbus Pharmaceuticals Holdings, Inc. CRBP
$3.82
▲ +8.52%
(+$0.30)
⬆️ Above Yest. High
🎢 High Beta
📅 Earnings This Week
Open
$3.43
Prev Close
$3.52
Day Range
$3.21 – $3.82
52W Range
$2.81 – $12.88
Market Cap
$68.08M
Beta
2.94
EPS (TTM)
$-6.17
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-10-24 |
| Shares Out. | 19,340,000 |
| Website | corbuspharma.com/ ↗ |
| Phone | 16179630103 |
| Employees | 36 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$35.0M |
| Free Cash Flow | -$86.7M |
| Total Assets | $127.0M |
| Total Liabilities | $24.7M |
| Equity | $102.2M |
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Corbus Pharmaceuticals Holdings, Inc. is a publicly traded company under the ticker symbol CRBP on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-11-01)